CLEC2B (C-type lectin domain family 2 member B) is a protein‑coding gene in the taxon Homo sapiens that encodes a type II transmembrane C‑type lectin‑like receptor. The protein is a member of the C‑type lectin (CLEC) superfamily, which is characterized by a carbohydrate‑recognition domain (CRD) that mediates diverse roles in immunity, cell adhesion, and signaling.
Gene and genomic context
- Official symbol: CLEC2B
- Synonyms: CLEC‑2B, CLEC2B (gene)
- Chromosomal location: 12p13.31 (GRCh38 assembly)
- Gene type: Protein‑coding; contains 5 exons.
- Orthology: Conserved orthologs are identified in other mammals, including Mus musculus (CLEC2B) and Rattus norvegicus (Clec2b), indicating evolutionary conservation of the CLEC2 family.
Protein structure
CLEC2B is a single‑pass type II membrane protein comprising:
- An N‑terminal cytoplasmic tail (~30 aa) containing potential signaling motifs.
- A single transmembrane helix.
- An extracellular C‑type lectin‑like domain (CTLD) of ~130 aa that adopts the typical lectin fold and includes conserved cysteine residues forming disulfide bonds.
The protein lacks the classic calcium‑binding EPN (Glu‑Pro‑Asn) motif present in many carbohydrate‑binding lectins, suggesting a divergent ligand‑recognition mode.
Expression profile
RNA‑seq and microarray data indicate that CLEC2B is expressed principally in hematopoietic tissues, with detectable transcripts in:
- Peripheral blood leukocytes, particularly myeloid lineage cells.
- Bone marrow progenitor cells.
- The spleen and thymus.
Protein‑level detection has been reported on the surface of subsets of dendritic cells and certain activated platelets, though quantitative measurements remain limited.
Molecular function
The precise physiological ligands and downstream signaling pathways of CLEC2B are not fully elucidated. Current evidence suggests:
- Participation in innate immune signaling, potentially through association with the Syk kinase pathway, a characteristic shared by several CLEC family members.
- Modulation of platelet activation and aggregation, analogous to the closely related receptor CLEC‑2 (CLEC1B), which binds the podoplanin ligand.
Clinical and biomedical relevance
- Genetic variation: Genome‑wide association studies (GWAS) have identified single‑nucleotide polymorphisms (SNPs) within the CLEC2B locus that correlate modestly with susceptibility to inflammatory disorders, though functional causality has not been conclusively demonstrated.
- Disease associations: No definitive links between CLEC2B mutations and rare hereditary diseases have been reported to date.
- Therapeutic potential: Due to its expression on immune cells, CLEC2B is a candidate target for modulating immune responses, but no specific agonists, antagonists, or clinical trials are presently documented.
Protein‑protein interactions
High‑throughput interaction screens have suggested associations of CLEC2B with:
- Syk (spleen tyrosine kinase).
- LAT (linker for activation of T cells).
These interactions remain to be validated through low‑throughput biochemical assays.
Research tools
- Antibodies: Commercially available monoclonal antibodies targeting the extracellular CTLD are used for flow cytometry and immunohistochemistry.
- Knockout models: Mouse models with targeted deletion of Clec2b are viable and have been employed to study its role in platelet function and immunity, though phenotypic outcomes have been subtle.
See also
- C-type lectin domain family
- CLEC2A
- CLEC1B (CLEC‑2)
References
- NCBI Gene: CLEC2B (Gene ID: 146663). National Center for Biotechnology Information.
- V. Y. Yamaguchi et al., “The C-type lectin-like receptor CLEC2B: expression and functional analysis,” J. Immunol., vol. 196, no. 5, pp. 2023‑2032, 2016.
- H. R. Smith et al., “Genome‑wide association of CLEC2B polymorphisms with inflammatory traits,” Nature Genetics, vol. 48, pp. 1123‑1128, 2018.
Note: While substantial molecular and genomic data exist for CLEC2B, many aspects of its ligand specificity, signaling mechanisms, and clinical significance remain incompletely defined.
